Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.
Autohomologous Immunotherapy, often called AHIT, is a treatment method that uses a patient’s own immune cells or biological material to help the body fight disease. The term "autohomologous" means the material comes from the same person receiving the treatment, not from a donor. In AHIT, blood cells or other biological material are collected from the patient, sometimes processed or activated outside the body, and then returned to the patient. Some versions of AHIT involve treating this material with ozone, a form of oxygen therapy, to stimulate the immune system. The goal is to boost the body’s natural defenses rather than directly attacking cancer cells with drugs or radiation.
AHIT is part of a broader group of treatments called immunotherapies, which aim to support the immune system’s ability to fight cancer. Unlike chemotherapy or radiation, which attack cancer cells directly, AHIT tries to strengthen the immune system’s natural response. Because the cells used come from the patient, there is usually a lower risk of rejection or serious immune reactions compared to treatments using donor cells. However, AHIT is not widely used in mainstream cancer care and is often considered experimental or complementary. It may be offered in clinical trials or specialized treatment plans when other treatments are not enough or to support the immune system.
Patients might hear about AHIT during discussions of immunotherapy options or when reviewing treatment plans that include personalized immune-based therapies. The term might appear in medical records, clinical trial descriptions, or alternative therapy literature. Some versions of AHIT involve processing the patient’s biological material with ozone, which is not part of standard cancer immunotherapy and is more common in complementary or alternative medicine. Because of this, AHIT may be mentioned in contexts outside mainstream oncology. It is important for patients to ask their care team what AHIT means in their specific case, how it works, and what to expect from the treatment.
AHIT should not be confused with other immune-related conditions or treatments that have similar abbreviations. For example, autoimmune heparin-induced thrombocytopenia (aHIT) is a rare immune reaction affecting blood platelets and is unrelated to autohomologous immunotherapy. AHIT is also different from well-known cancer immunotherapies like checkpoint inhibitors or CAR-T cell therapy, which have more established roles and scientific support in cancer care. Understanding that AHIT uses the patient’s own cells or material helps set realistic expectations about its benefits and risks.
If AHIT is mentioned in your care or research, it is important to ask your healthcare providers about its purpose, how it differs from standard immunotherapy, and what evidence exists regarding its safety and effectiveness. Questions to consider include: What is the goal of AHIT in my care? What benefits and risks should I expect? How does AHIT fit with my current treatment plan? Is AHIT part of a clinical trial or an alternative therapy? Getting clear answers can help you make informed decisions about your cancer care.
AHIT is not a standard cancer treatment and is not included in most conventional cancer treatment guidelines. It is described in oxidative therapy literature and is considered a patented German method involving ozone-processed autologous material. Because it is not part of mainstream cancer immunotherapy, AHIT should be viewed as a distinct approach within complementary or experimental therapies. Reading about AHIT alone can be confusing, so it is best understood by discussing it with your oncology team to see how it relates to your overall care.
This information about AHIT is provided to help you learn about this treatment option but does not replace medical advice. Treatment decisions should always be made with your healthcare providers, who can consider your unique situation and the best available evidence. If you encounter AHIT in your care or research, the next step is to talk openly with your doctors or nurses. Ask for clear explanations about what AHIT involves, how it might affect your treatment, and whether it is appropriate for you. This will help you make safe, informed choices about your cancer care.
Public source information used for this glossary entry includes: